Sean Myers, DO
Family Medicine · Kingman, AZNPI 1396123915
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $425 and has fallen 71.7% since, to $120 in 2021.
Across 43 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$128
- Johnson & Johnson$114
- Amgen$75
- AbbVie$70
- Sanofi-aventis U.S. LLC$64
- GSK$59
- plus $136 from 8 others
What the payments were for
- Food & beverage$646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $128 |
| Johnson & Johnson | 8 | $114 |
| Amgen | 5 | $75 |
| AbbVie(2 entities) | 4 | $70 |
| Sanofi-aventis U.S. LLC | 5 | $64 |
| GSK | 4 | $59 |
| Digital Diagnostics Inc. | 1 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $23 |
| Eisai Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $14 |
| Merck | 1 | $13 |
| Pfizer | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$646 in reported general payments places this provider in the 65th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $98,278 |
| OzempicSemaglutide | 66 | $88,698 |
| TrulicityDulaglutide | 60 | $67,675 |
| JanuviaSitagliptin Phosphate | 41 | $56,060 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $45,485 |
| XareltoRivaroxaban | 36 | $44,771 |
| FarxigaDapagliflozin Propanediol | 31 | $42,200 |
| RybelsusSemaglutide | 23 | $38,749 |
| LinzessLinaclotide | 23 | $30,622 |
| JardianceEmpagliflozin | 17 | $28,347 |
| MounjaroTirzepatide | 27 | $26,417 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $15,915 |
| Spiriva RespimatTiotropium Bromide | 15 | $14,821 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $13,120 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $128 | $127,44789 claims |
| PfizerEliquis | $13 | $98,27883 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $12 | $94,09287 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $59 | $62,80488 claims |
| MerckJanuvia | $13 | $56,06041 claims |
| Johnson & JohnsonXarelto | $114 | $44,77136 claims |
| AbbVieLinzess | $70 | $30,62223 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $64 | $10,05312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Kingman
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
- Suzanne BentzMesa$174K
- Brent AllanParadise Valley$108K
- Ahmed AghaPhoenix$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.